具有侵袭性特征的早期非小细胞肺癌行肺段切除术的肿瘤学结局:一项多中心研究
这项多中心研究纳入2010年1月至2019年12月间3家机构收治的321例术前CT示实性成分为主(实性肿瘤比>50%)、全肿瘤≤2 cm且病理存在淋巴管侵袭、血管侵袭、胸膜侵袭或淋巴结转移的NSCLC患者,比较肺段切除术与肺叶切除术的复发累积发生率。肺段切除术80例(24.9%),肺叶切除术241例(75.1%);两组5年复发累积发生率无显著差异(17.2% vs 27.8%,P=0.135),倾向性评分匹配后亦无显著差异(19.1% vs 19.2%,P=0.650);多变量分析中肺段切除术不是复发累积发生率更差的显著预测因素(P=0.920)。结论认为,无论是否存在淋巴管侵袭、血管侵袭、胸膜侵袭或淋巴结转移,肺段切除术对临床早期NSCLC均可行。
要点
- 321例具有侵袭性特征的早期NSCLC中,肺段切除术80例(24.9%),肺叶切除术241例(75.1%)。
- 肺段切除组5年复发累积发生率为17.2%,肺叶切除组为27.8%,两组无显著差异(P=0.135)。
- 倾向性评分匹配后两组5年复发累积发生率无显著差异(19.1% vs 19.2%,P=0.650)。
核心结论
- 肺段切除术对临床早期NSCLC可行,无论是否存在淋巴管侵袭、血管侵袭、胸膜侵袭或淋巴结转移。
研究设计与样本
- 多中心研究,纳入2010年1月至2019年12月间3家机构收治的321例患者。
- 纳入标准为:行肺叶切除术或肺段切除术的NSCLC且病理存在淋巴管侵袭、血管侵袭、胸膜侵袭或淋巴结转移;术前CT示淋巴结阴性、实性成分为主(实性肿瘤比>50%);全肿瘤≤2 cm。
- 比较肺段切除术与肺叶切除术后的复发累积发生率。
主要发现
- 肺段切除术80例(24.9%),肺叶切除术241例(75.1%)。
- 肺段切除组5年复发累积发生率为17.2%,肺叶切除组为27.8%,两组无显著差异(P=0.135)。
- 倾向性评分匹配队列中,肺段切除组5年复发累积发生率为19.1%,肺叶切除组为19.2%,两组无显著差异(P=0.650)。
- 采用逆概率处理加权和多变量分析,肺段切除术不是复发累积发生率更差的显著预测因素(P=0.920)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Segmentectomy can provide oncologically acceptable results for small-sized non-small-cell lung cancer (NSCLC). However, in cases of NSCLC with pathological invasive characteristics such as lymphatic invasion (LY), vascular invasion (V), pleural invasion (PL) and/or lymph node metastasis, the feasibility of segmentectomy is not known. METHODS: The patients included in the study (i) underwent lobectomy or segmentectomy for NSCLC with invasive characteristics such as LY, V, PL or pathological lymph node metastasis; (ii) presented with a node-negative, solid component-predominant tumour (consolidation tumour ratio >50%) on preoperative computed tomography; (iii) had a whole-tumour size of 2 cm or less; and (iv) presented between January 2010 and December 2019 to one of the 3 institutions. Cumulative incidences of recurrence (CIRs) after segmentectomy and lobectomy were compared. RESULTS: A total of 321 patients were included. Segmentectomy and lobectomy were performed in 80 (24.9%) and 241 (75.1%) patients, respectively. There was no significant difference in CIR between segmentectomy (5-year CIR rate, 17.2%) and lobectomy patients (5-year CIR rate, 27.8%, P = 0.135). In the propensity score-matched cohort, there was no significant difference in CIR between segmentectomy (5-year CIR rate, 19.1%) and lobectomy patients (5-year CIR rate, 19.2%; P = 0.650). In the multivariable analysis using inverse probability of treatment weighting and surgical method, segmentectomy was not a significant predictor of worse CIR (P = 0.920). CONCLUSIONS: Segmentectomy is feasible for clinically early-stage NSCLC irrespective of the presence of LY, V, PL or lymph node metastasis.
引用
- Kagimoto A, Tsutani Y, Shimada Y, et al. Oncological outcome of segmentectomy for early-stage non-small-cell lung cancer with invasive characteristics: a multicentre study. Eur J Cardiothorac Surg. 2022. PMID: 35150248. doi:10.1093/ejcts/ezac055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。